Tracked deals
9
9 tracked deals across 2015-2026.
Pharmaceuticals Buyers & Acquisitions in New York
Buyer mix
Mixed buyer set
8 pe · 5 strategic
Top trend
Volume peaked in 2026
2 tracked deals announced in 2026.
Primary Insight
What Stands Out
- Eli Lilly and Company pursued an oncology-focused acquisition of Ajax Therapeutics, Inc. to expand its pipeline in myelofibrosis (AJ1-11095, a Type II JAK2 inhibitor).
- TopGum Industries Ltd. completed an acquisition of U.S. gummy manufacturing operations and paired it with a long-term commercial partnership for store-brand retail distribution.
- Rights-focused and R&D-driven moves appear alongside M&A, including Axsome Therapeutics securing exclusive global rights to AZD7325 through its acquisition of Baergic Bio.
- Growth and platform investment activity includes Long Island-based private-label and generic-pharmaceutical expansion, supported by investor groups such as RF Investment Partners and an investment consortium including PNC Bank.
| Common motif | Examples from New York deals |
|---|---|
| Pipeline or compound rights | Eli Lilly and Company → Ajax Therapeutics; Axsome Therapeutics → Baergic Bio |
| Manufacturing + distribution | TopGum Industries Ltd. → gummy operations; Geritrex → OTC liquid nasal products |
| Investor-led platform building | RF Investment Partners / Aquimont Capital / Miramar Equity Partners; SK Capital Partners / Comvest Partners |
Build a buyer list for your Pharmaceuticals deal
Find buyers actively acquiring pharmaceuticals companies.
Find buyers like these for your dealBuyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Aquimont Capital | 1 | Healthcare-focused investment firm that partners with nic... | PE |
| Axsome Therapeutics | 1 | Public biopharmaceutical company developing novel therapi... | Strategic |
| BelHealth Investment Partners | 1 | Healthcare-focused private equity firm investing in lower... | PE |
| Biocodex Group | 1 | French pharmaceutical company focused on microbiota care,... | Strategic |
| Comvest Partners | 1 | Operationally focused middle-market private investment fi... | PE |
| Eli Lilly and Company | 1 | Global biopharmaceutical company with an oncology franchi... | Strategic |
| Geritrex | 1 | Manufacturer and distributor of topical generic OTC produ... | Strategic (PE-backed) |
| Leedon Park Capital LLC | 1 | Middle-market private equity firm focused on long-term pa... | PE |
| Miramar Equity Partners | 1 | Private equity platform of Miramar Holdings (a Dallas-bas... | Family Office |
| NewSpring Mezzanine | 1 | Middle-market private equity firm offering growth equity,... | PE |
Acquisition Volume in Pharmaceuticals in New York by Year
Last 5 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
- Buyer
- TopGum Industries Ltd.
- Target
- P26L Developments LLC, P L Developments LLC, PL Developments LLC (PLD)
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Buyout
TopGum Industries Ltd. completed the acquisition of the U.S. gummy manufacturing operations of P26L/PL Developments LLC (PLD). TopGum also entered a long-term commercial partnership with PLD under which PLD will commercialize and distribute TopGum-manufactured gummy products to leading U.S. retailers under store-brand labels.
-
April 27, 2026
- Buyer
- Eli Lilly and Company
- Target
- Ajax Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Buyout
Eli Lilly and Company announced a definitive agreement to acquire Ajax Therapeutics, Inc. in a deal valued at up to $2.3 billion, including upfront and milestone-based payments. The acquisition is intended to expand Lilly’s oncology pipeline with Ajax’s lead candidate, AJ1-11095, a Type II JAK2 inhibitor in Phase 1 development for myelofibrosis, including patients previously treated with Type I JAK2 inhibitors.
-
- Buyer
- Axsome Therapeutics
- Target
- Baergic Bio
- Seller
- Avenue Therapeutics, Baergic Bio shareholders
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Buyout
Axsome Therapeutics acquired a 100% equity interest in Baergic Bio (a subsidiary of Avenue Therapeutics) and amended Baergic Bio's license with AstraZeneca to obtain exclusive global rights to AZD7325, an early‑stage selective GABAA α2,3 receptor modulator for epilepsy. The deal includes a $0.3 million upfront payment to Baergic Bio shareholders and potential development, regulatory, sales‑based milestones and tiered royalties to Avenue Therapeutics and AstraZeneca as described in the purchase and amended license agreements.
-
September 2, 2025
- Buyer
- PharmaCyte Biotech, Inc.
- Target
- TNF Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Growth capital
PharmaCyte Biotech, Inc. increased its equity stake in TNF Pharmaceuticals, Inc. by $3.0 million to support TNF's recent license agreement with LightSolver for a light-based compute accelerator intended for cryptocurrency and blockchain applications. The investment is positioned to help TNF execute a strategic pivot tied to the new license; PharmaCyte said it remains well-capitalized and may pursue further portfolio opportunities.
-
September 19, 2024
- Buyer
- RF Investment Partners, Aquimont Capital, Miramar Equity Partners
- Target
- Altro Pharmaceuticals, Amici Pharmaceuticals
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Growth capital
RF Investment Partners announced a platform investment in Long Island-based sister companies Altro and Amici Pharmaceuticals, partnering with Aquimont Capital and Miramar Equity Partners to support growth in the companion animal/veterinary pharmaceutical market. The investment provides flexible debt and equity capital to expand sourcing, manufacturing and distribution capabilities for generic pharmaceuticals that serve both veterinary and human end markets.
-
November 17, 2022
- Buyer
- Biocodex Group
- Target
- Hilma
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Buyout
French pharmaceutical group Biocodex has acquired a majority stake in Hilma, a U.S.-based natural remedies start-up founded by Hilary Quartner, Nina Mullen and Lily Galef. The deal gives Biocodex a stronger foothold in the U.S. digestive-health and women’s-health segments and will help scale Hilma’s omnichannel retail strategy (DTC plus 750+ stores including Target).
-
September 7, 2022
- Buyer
- SK Capital Partners, Comvest Partners
- Target
- VanDeMark Chemical, Inc.
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Growth capital
Funds advised by SK Capital Partners have made a strategic investment in VanDeMark Chemical, a Comvest Partners portfolio company headquartered in Lockport, New York. Comvest remains a co-owner; the investment will accelerate VanDeMark's growth and deepen its focus on life-science specialty chemistries, with SK Capital supporting organic and inorganic expansion.
-
April 27, 2021
- Buyer
- NewSpring Mezzanine (NewSpring Capital), Tecum Capital (Tecum Capital Partners), Leedon Park Capital LLC, PNC Bank (PNC Financial Services Group)
- Target
- Spirit Pharmaceuticals LLC
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Growth capital
An investor group led by NewSpring Mezzanine, alongside Tecum Capital, Leedon Park Capital and PNC Bank provided a growth capital injection into Spirit Pharmaceuticals LLC, backing CEO and founder Ajoy Joshi. The funding will support the Long Island-based private-label developer, packager and distributor of over-the-counter pharmaceutical products as it expands capacity (two additional facilities, 11 packaging lines) and deepens relationships with big-box retailers, medical distributors and e-commerce customers.
-
November 9, 2015
- Buyer
- Geritrex, BelHealth Investment Partners
- Target
- PurinePharma
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Addon
Geritrex, a BelHealth Investment Partners portfolio company, has acquired the business and assets of PurinePharma, a private-label manufacturer and distributor of OTC liquid nasal, allergy, and cough & cold products based in Massena, New York. The add-on expands Geritrex's manufacturing capabilities into liquid dosage forms, provides access to the retail private-label channel and export markets, and adds a CGMP-approved manufacturing facility in upstate New York.
Build a buyer list for your Pharmaceuticals deal
Find buyers actively acquiring pharmaceuticals companies.
Frequently Asked Questions
What types of pharmaceuticals deals are featured in New York?
The page highlights a mix of acquisitions, majority-stake buys, growth and platform investments, and deals that secure commercialization or global rights—often paired with manufacturing and distribution expansion.
Which New York transactions involve pipeline expansion or drug rights?
Eli Lilly and Company announced an acquisition of Ajax Therapeutics, Inc. to expand its oncology pipeline, and Axsome Therapeutics acquired Baergic Bio to obtain exclusive global rights related to AZD7325.
Are there transactions focused on private-label manufacturing and retail distribution?
Yes. TopGum Industries Ltd. completed a U.S. gummy manufacturing acquisition and entered a long-term commercialization/distribution partnership for store-brand labels. Spirit Pharmaceuticals LLC funding also targeted expansion of private-label packaging and distribution for OTC products.
Is activity limited to New York City?
No—listed deals reference other parts of the state as well, including Long Island-based operations and an upstate New York manufacturing facility tied to Geritrex’s acquisition of PurinePharma.
Related Acquisition Pages
Pharmaceuticals Buyers & Acquisitions
Pharmaceuticals Buyers & Acquisitions in Canada
Private Equity-Backed Pharmaceuticals Buyers
Pharmaceuticals Acquisitions in 2026
Pharmaceuticals Acquisitions in 2025
Pharmaceuticals Acquisitions in 2024
Pharmaceuticals Acquisitions in 2022
Pharmaceuticals Acquisitions in 2021
Pharmaceuticals Acquisitions in 2015
Acquisitions in New York
Private Equity-Backed Acquisitions in New York
Acquisitions in New York in 2026